

**Supplementary Table S1.** Select Patient Baseline Characteristics by Time from Last Anti-PD-1 Therapy

Characteristic	Median time from last dose of anti-PD-1 therapy to receipt of study drug	
	<6.7 months (n = 16)	≥6.7 months (n = 16)
Median number of prior therapies for metastatic/locally advanced disease, n	4	5
ECOG PS, n (%)		
0	12 (75.0)	7 (43.8)
1	4 (25.0)	9 (56.3)

ECOG PS, Eastern Cooperative Oncology Group performance status; PD-1, programmed cell death-1.